Sunshine Biopharma Continues Its Efforts to Re-Domicile in Canada for Bus. Expansion & Financing Opportunities for Adva-27a C...
04 February 2014 - 1:00PM
Marketwired
Sunshine Biopharma Continues Its Efforts to Re-Domicile in Canada
for Business Expansion and Financing Opportunities for Adva-27a
Cancer Drug Candidate
MONTREAL, QC--(Marketwired - Feb 4, 2014) - Sunshine Biopharma
Inc. (OTCQB: SBFM), a pharmaceutical company focused on the
research, development and commercialization of proprietary drugs
for the treatment of various forms of cancer, today announced that
it is continuing its efforts to re-domiciling the Company in Canada
in order to capitalize on management's belief that by doing so, the
Company will generate additional business expansion opportunities
and gain access to financing programs available to Canadian
corporations. On January 31, 2014, the Company filed an S-4
Registration Statement wherein it is attempting to re-domicile to
Canada from Colorado.
"We are very pleased with the progress we have made thus far in
our efforts to re-domicile the Company in Canada," said Dr. Steve
N. Slilaty, Chief Executive Officer of Sunshine Biopharma. "We
are anxious to complete the re-domiciling process as we have
attendant growth and financing opportunities that we believe are
available to us once we have completed this action. This is
important for the Company's business strategy overall and for our
Adva-27a anticancer drug candidate as we advance towards clinical
trials for multidrug resistant breast cancer and pancreatic
cancer."
About Adva-27a
Adva-27a is Sunshine Biopharma's lead anticancer compound, a
small molecule that has recently been shown to be effective at
killing multidrug resistant breast cancer cells, small-cell lung
cancer cells, uterine sarcoma cells and pancreatic cancer cells
(Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432,
October 2012). Adva-27a is currently in the IND-Enabling stage
of development. The original U.S. patent covering Adva-27a was
issued on August 7, 2012 under US patent number 8,236,935.
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not
strictly historical, including statements as to revenue
projections, business strategy, outlook, objectives, future
milestones, plans, intentions, goals, future financial conditions,
future collaboration agreements, the success of the Company's
development, events conditioned on stockholder or other approval,
or otherwise as to future events, such statements are
forward-looking, and are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
The forward-looking statements contained in this release are
subject to certain risks and uncertainties that could cause actual
results to differ materially from the statements made.
For Additional Information Contact: Camille Sebaaly CFO Sunshine
Biopharma Inc. Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com www.sunshinebiopharma.com